All In Biotech

Drug Trial Radar · NCT01245569

A Study in Patients With Chronic Obstructive Pulmonary Disease

A 12-week, Multicentre, Multinational, Randomized, Double-blind, Double-dummy, 2-arm Parallel Group Study Comparing the Efficacy and Safety of Foster® 100/6 (Beclomethasone Dipropionate 100 µg Plus Formoterol 6 µg/Actuation), 2 Puffs b.i.d., Versus Seretide® 500/50 (Fluticasone 500 µg Plus Salmeterol 50 µg/Actuation), 1 Inhalation b.i.d., in Patients With Chronic Obstructive Pulmonary Disease

Last checked: Nov 20, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 419 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

419

Actual

Start

Apr 12, 2011

Primary completion

Mar 13, 2012

Study completion Mar 13, 2012

Sponsor

Lead sponsor
Chiesi Farmaceutici S.p.A.Industry
Sponsor type
Industry
First posted
Nov 22, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study was to demonstrate the superiority of Foster® 100/6 (two puffs b.i.d.) versus Seretide® 500/50 (one inhalation b.i.d.), in terms of pulmonary function (AUC0-30min standardized by time of change from pre-dose in FEV1) after drug inhalation in the morning of day 1, and the equivalence between Foster® 100/6 (two puffs b.i.d.) and Seretide® 500/50 (one inhalation b.i.d.) in terms of Transition Dyspnoea Index (TDI) score at day 84 in patients with COPD. The secondary objectives of the study were: * To evaluate the efficacy of the test treatments in terms of additional spirometric parameters and of clinical outcome measures; * To assess the safety and tolerability; * To perform an exploratory analysis evaluating the consumption of resources deriving from COPD management in the perspective of the Healthcare System.

Conditions

  • Chronic Obstructive Pulmonary Disease

Interventions

  • Beclomethasone Dipropionate - FormoterolDrug

    Administered via a pressurized metered-dose inhaler

  • Fluticasone - SalmeterolDrug

    Administered via a pressurized metered-dose inhaler

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area Under the Curve (AUC) 0-30min Standardized by Time of Change From Pre-dose in Forced Expiratory Volume in One Second (FEV1) in the Morning of Day 1Time frame: on Day 1 (V2)
  2. Transition Dyspnoea Index (TDI) Score at Day 84Time frame: Day 84 (V5)

Locations

68 sites in 10 countries. Site status is shown where the registry gives one.

  • Aarhus University Hospital

    Aarhus, Denmark

  • Bispebjerg Hospital

    Copenhagen, Denmark

  • Dept. of Cardiology and Respiratory Medicine

    Copenhagen, Denmark

  • Gentofte Hospital

    Gentofte Municipality, Denmark

  • Odense University Hospital

    Odense, Denmark

  • Centre Hospitalier

    Toulon, France

  • Praxis Dr. Jorg Kampschulte

    Berlin, Germany

  • Praxis Dr. Jörg Winkler

    Leipzig, Germany

  • KLB Healthresearch

    Lübeck, Germany

  • KLD Helthreseach

    Lübeck, Germany

  • SMO.MD GmbH Zentrum für Klinische Studien

    Magdeburg, Germany

  • Pneumologische Gemeinschaftspraxis Saarbrücken

    Saarbrücken, Germany

  • Fachinternistische Gemeinschafts

    Wedel, Germany

  • Pneumologische Praxis Dr Redlich

    Wiesloch, Germany

  • Gemeinschaftspraxis für Pneumologie

    Wuppertal, Germany

  • Dr. Kenessey Albert Kórház - Rendelőintézet

    Balassagyarmat, Hungary

  • Békés Megyei Képviselő-testület Pándy Kálmán Kórház

    Békés, Hungary

  • Szabolcs-Szatmár-Bereg Megyei Önkormányzat Jósa András Oktató Kórház

    Budapest, Hungary

  • Centrum-Tüdőgyógyászati Klinika

    Debrecen, Hungary

  • Bács-Kiskun Megeyi Önkormanyzat...

    Kecskemét, Hungary

  • Karolina Kórház és Rendelőintézet Tüdőgyógyászat

    Mosonmagyaróvár, Hungary

  • Békés Megyei Képviselő-testület Pándy Kálmán Kórház

    Nyíregyháza, Hungary

  • Jósa András Hospital

    Nyíregyháza, Hungary

  • Chiesi Clinical Centre Szigetszentmiklös

    Szigetszentmiklös, Hungary

  • Ospedale Sant'Orsola-Malpighi

    Bologna, Italy

  • A.O. Policlinico

    Catania, Italy

  • A.O. S. Gerardo

    Monza, Italy

  • Azienda Ospedaliera Monaldi

    Naples, Italy

  • Università di Pisa

    Pisa, Italy

  • IRCCS San Raffaele La Pisana

    Roma, Italy

  • Policlinico Umberto I - VIII Padiglione

    Rome, Italy

  • NZOZ "Non Nocere"

    Gdansk, Poland

  • Niepubliczny Zakład Opieki Zdrowotnej "PROFILAKTYKA"

    Koszalin, Poland

  • Szpital Specjalistyczny im Jana Pawła II

    Krakow, Poland

  • Szpital Uniwersytecki w Krakowie

    Krakow, Poland

  • Prywatny Gabinet Specjalistyczny

    Lodz, Poland

  • Samodzielny Publiczny Szpital Kliniczny

    Szczecin, Poland

  • Chorób Płuc

    Warsaw, Poland

  • Gabinet Lekarski SERIA IWONA GRZELEWSKA-RZYMOWSKA

    Warsaw, Poland

  • Instytut Gruźlicy i Chorób Płuc. Zakład Diagnostyki i Leczenia Niewydolności Oddychania

    Warsaw, Poland

Showing 40 of 68 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.